Biomacromolecules:安全的减肥药即将问世,再也不必担心减肥药的副作用了!

2015-08-03 sunshine 译 MedSci原创

为了对抗全球肥胖流行的趋势,科学家们正在开发一种新的化合物,称为“胶束螯合剂聚合物”或MSPs,可防止机体吸收脂肪颗粒,从而达到减轻体重的目的。据研究报道,研究人员已在大鼠身上进行了这种药物的实验,该研究成果发表于《生物大分子》。研究表明,全球范围内,肥胖的发病率逐年升高。超重和肥胖的治疗主要包括饮食、运动、手术以及服用处方药。但是目前可有效减肥的药物可能存在较严重的副作用,包括可增加心血管疾病及

为了对抗全球肥胖流行的趋势,科学家们正在开发一种新的化合物,称为“胶束螯合剂聚合物”或MSPs,可防止机体吸收脂肪颗粒,从而达到减轻体重的目的。据研究报道,研究人员已在大鼠身上进行了这种药物的实验,该研究成果发表于《生物大分子》。

研究表明,全球范围内,肥胖的发病率逐年升高。超重和肥胖的治疗主要包括饮食、运动、手术以及服用处方药。但是目前可有效减肥的药物可能存在较严重的副作用,包括可增加心血管疾病及抑郁症的发生危险。因此,Cory Berkland及其同事开始着手寻找新的减肥药物。

针对人体脂肪的吸收过程,研究者设计了一类聚合物,可捕捉肠道内称为胶束的脂肪颗粒,因此这些脂肪颗粒可避免机体的消化吸收,最后可经肠道排出体外。实验过程中,摄入MSPs的小鼠粪便中的甘油三酯(主要的膳食脂肪)的量较对照组小鼠粪便中甘油三酯的量高九到十倍。此外,研究人员表示,因为MSPs 是可通过身体被吸收,所以可为肥胖的长期治疗提供一个安全的治疗方法。

原始出处:

Toward a safe antiobesity drug that could block fat absorption.Science Daily,July 29, 2015.

Jian Qian, Bradley P. Sullivan, Cory Berkland. pH-Responsive Micelle Sequestrant Polymers Inhibit Fat Absorption. Biomacromolecules, 2015; 150717100610007

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
    2016-05-10 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
    2015-08-26 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
    2015-08-04 shuaijing1986

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
    2015-08-04 10518094zz
  8. [GetPortalCommentsPageByObjectIdResponse(id=1857357, encodeId=332b185e35722, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sat Feb 13 10:27:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917180, encodeId=5b5f191e18074, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 10 19:27:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995924, encodeId=5f0019959242c, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Aug 26 21:27:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824199, encodeId=89501824199d4, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Sep 26 05:27:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34366, encodeId=bfca343662b, content=额, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78351636049, createdName=shuaijing1986, createdTime=Tue Aug 04 17:15:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286157, encodeId=73f2128615e96, content=<a href='/topic/show?id=3be5312e656' target=_blank style='color:#2F92EE;'>#减肥药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31276, encryptionId=3be5312e656, topicName=减肥药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400329, encodeId=5ab21400329d2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Tue Aug 04 15:27:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34096, encodeId=28c334096da, content=肥胖者的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Mon Aug 03 10:11:00 CST 2015, time=2015-08-03, status=1, ipAttribution=)]
    2015-08-03 Messichen1992

    肥胖者的希望

    0

相关资讯

FDA重审3只被拒减肥药 减肥新药审批迎来拐点

2012年以来,美国FDA将对此前在2010年被拒绝的3只减肥药物进行重新审查。而至于这3只药物可否获批,医学界大多持观望的态度。医学界怀疑的并不是这些减肥药的疗效,而是它们的安全性,虽然业界也非常渴望在这一治疗领域取得重大突破。 自从上一只减肥药物获批销售以来,时间已经整整过去了13年。最后一只获得批准的减肥药是罗氏生产的赛尼可(Xenical),于1999年获得批准。 Orlistat:审

为什么美国医生要限制减肥药的销量?

  (原标题:为什么美国医生不多开点减肥药?) 6月11日美国FDA称将推迟决定是否批准一个新的减肥药物,这个药是Orexigen的Contrave,这次FDA把做决定的日子往后推了3个月。若最终获批,它将成为近年来获批上市的第3个减肥药物。不过,按目前的情况来看,即使能成功上市,也和另外两个减肥药Qsymia和Belviq一样,不会有很大的销量。 根据美国CDC的统计数据

Zafgen减肥药beloranib二期研究成果显著

Zafgen公司公布了关于其研发的治疗肥胖症的药物beloranib二期临床结果,数据令人印象深刻。数据显示,在不改变饮食和锻炼强度的情况下,实验组肥胖症病人的体重出现明显降低。该药物是Zafgen从韩国的CKD公司获得授权。 据研究显示,肥胖症是引发二型糖尿病的最大因素之一 详细英文报道: CHICAGO--Zafgen has revealed some impressive weigh

吃减肥药时会出现的稀奇事——《华盛顿邮报》

2007年,美国食品和药物管理局首次批准非处方减肥药。任何人无需处方便可购买这种名为Alli的减肥药。只要服用它的人依然保持健康的生活方式就可以达到减肥的目的。最后这一点可以说服服用减肥药的人坚持健康饮食,好好锻炼身体,这一点很重要但常常被很多减肥药所忽视。Alli制造商GlaxoSmithKline却意识到了这一点,而且它的营销广告也不会让人们觉得这是某种灵丹妙药。但要让人们相信这药只起辅助作用

Gelesis减肥药Gelesis100获得理想数据

总部设在波士顿的生物技术公司Gelesis最近宣布公司开发的口服减肥药Gelesis100即将进入上市审批阶段。Gelesis100是一种颗粒物质,患者在餐前服用该药物会抑制其食欲最终达到减肥效果。临床研究显示,小剂量服用该药物时,患者平均体重降低约6.1%,而高剂量组与对照组没有差异。公司负责开发Gelesis100的Professor Arne Astrup认为Gelesis100的结果

葛兰素史克在美国召回非处方减肥药Alli

北京时间3月28日凌晨消息,英国制药商葛兰素史克周四宣布,由于部分批次可能被篡改,包含了一种非正宗的产品,正在从美国以及波多黎各零售商处自愿召回所有的Alli减肥产品。 葛兰素史克在声明中说,收到来自七个州消费者就Alli的药瓶中装有不是Alli产品的片剂和胶囊的查询要求。在这些消费者投诉中,Alli减肥产品的瓶中发现有多种不同形状和颜色的片剂及胶囊。其中的一些药物没有标签,防伪封印也不是正宗的